WHAT IS FIBROSIS?

Fibrosis is a pathological condition characterized by excessive extracellular matrix (ECM) accumulation, leading to tissue scarring and organ dysfunction. This process is a response to chronic injury or inflammation and involves various cellular mechanisms, including fibroblast activation, epithelial-mesenchymal transition (EMT), and persistent signaling pathways.

Unveiling fibrotic diseases with AnyGenes® qPCR arrays

AnyGenes® provides cutting-edge qPCR arrays specifically designed to study fibrotic disease at the molecular level. Our tools empower researchers to:

Analyze gene expression changes associated with fibrotic disease development and progression.
Explore key biomarkers like transforming growth factor-beta (TGF-β), collagen types, and matrix metalloproteinases (MMPs).
Investigate signaling pathways such as TGF-β, Wnt/β-catenin, and PI3K/Akt involved in fibrotic diseases.

AnyGenes qPCR arrays for fibrosis research – analyze gene expression in tissue scarring and fibrotic diseases.

Discover our advanced qPCR arrays for Fibrotic Diseases research.

The TGF-β, WNT, and YAP/TAZ signaling pathways converge.

KEY MECHANISMS AND BIOMARKERS IN FIBROSIS

Fibrotic diseases are driven by intricate mechanisms involving multiple cell types and pathways. Understanding these processes is crucial for developing effective therapeutic strategies.

Fibroblast Activation: Fibroblasts transform into myofibroblasts, producing ECM proteins like collagen and fibronectin.
TGF-β Signaling: A master regulator of fibrotic diseases, it promotes ECM deposition and inhibits ECM degradation.
Matrix Metalloproteinases (MMPs): Enzymes that remodel ECM, playing dual roles in disease progression and resolution.
Inflammatory Cytokines: Interleukins and tumor necrosis factor-alpha (TNF-α) contribute to chronic inflammation and tissue scarring.

TYPES OF FIBROSIS

The types of fibrotic diseases are classified based on the affected organs or tissues.

Liver Fibrosis: Associated with chronic liver diseases such as hepatitis, alcoholism, or non-alcoholic fatty liver disease (NAFLD). It can progress to cirrhosis and liver failure if untreated.
Pulmonary Fibrosis: Characterized by thickened and scarred lung tissue, reducing oxygen transfer. It includes idiopathic pulmonary fibrosis (IPF) and fibrotic disease caused by infections or environmental exposures.
Cardiac Fibrosis: Involves stiffening of heart tissue, often resulting from chronic hypertension, myocardial infarction, or other cardiac diseases. It leads to impaired cardiac function and heart failure.
Renal Fibrosis: A common consequence of chronic kidney disease (CKD). It Damages renal tissue, impairing the kidney's ability to filter blood effectively.
Skin Fibrosis: Seen in conditions like scleroderma, involving hardening and thickening of the skin. It can also occur as a result of severe burns or trauma.
Pancreatic Fibrosis: Associated with chronic pancreatitis or cystic fibrosis. It impairs the pancreas's ability to produce enzymes and regulate blood sugar.
Systemic Fibrosis: Seen in diseases like systemic sclerosis, affecting multiple organs and tissues.

ADVANCING FIBROTIC DISEASE RESEARCH WITH ANYGENES®

Our qPCR arrays enable precise and reproducible analysis of genes involved in fibrotic diseases, providing essential data for understanding:

The molecular basis of tissue scarring.
The role of signaling pathways in fibrotic conditions.
Potential therapeutic targets for anti-fibrotic treatments.

Explore the complexities of fibrotic diseases with AnyGenes®. Our advanced qPCR tools empower researchers with precise data to accelerate research and uncover innovative solutions. Whether studying biomarkers, analyzing key signaling pathways, or targeting disease mechanisms, AnyGenes® is your partner in achieving groundbreaking discoveries.

FUTURE DIRECTIONS IN FIBROTIC DISEASE RESEARCH

Fibrotic disease remains a significant challenge due to its complexity and the lack of effective treatments for many fibrotic diseases. Current research focuses on:

Novel Biomarkers: Identifying specific and sensitive biomarkers for early diagnosis, prognosis, and treatment monitoring.
Therapeutic Targets: Developing drugs targeting key signaling pathways like TGF-β, Wnt/β-catenin, and PI3K/Akt to halt or reverse fibrotic disease.
Personalized Medicine: Leveraging gene expression profiling to tailor treatments to individual patient profiles.
Regenerative Approaches: Exploring therapies aimed at promoting tissue regeneration and reversing fibrotic scarring.

With AnyGenes® qPCR arrays, researchers can delve deeper into these emerging areas, contributing to breakthroughs in the understanding and treatment of fibrotic diseases. Empower your fibrotic disease research with precision tools that drive impactful discoveries.

(1) Murtha LA et al. The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis. Front Physiol. (2017);8:777.

(2) Li X et al. Drugs and Targets in Fibrosis. Front Pharmacol. (2017);8:855.

(3) Falke LL et al. Diverse origins of the myofibroblast—implications for kidney fibrosis. Nat Rev Nephrol. (2015);11(4):233-44.

(4) Ng HH et al. Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways. Mol Cell Endocrinol. (2019);487:59-65.

(5) Piersma B et al. Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge. Front Med (Lausanne). (2015);2:59.

FIBROSIS SIGNALING PATHWAY BIOMARKER LIST

Customize your own signaling pathways (SignArrays®) with the factors of your choice!
Simply download and complete our Personalized SignArrays® information file and send it at contact@anygenes.com to get started on your project.

You can check the biomarker list included in this pathway, see below:

Species : Homo sapiens (human)

Signaling Pathways	Product ref	Informations
Fibrosis	FI1H1	List infos

Species : Mus musculus (mouse)

Signaling Pathways	Product ref	Informations
Fibrosis	FI1M1	List infos

Species : Rattus norvegicus (rat)

Signaling Pathways	Product ref	Informations
Fibrosis	*******	List In progress...

Species : Sus Scrofa (Pig)

Signaling Pathways	Product ref	Informations
Fibrosis	*******	List In progress...

For more information on prices, please click here